In this minority of clinicopathological RCC subtypes where phase III randomized studies are lacking, preferred frontline therapy consists of a VEGFR TKI, usually either cabozantinib or sunitinib, particularly in papillary tumors, although outcomes are usually inferior compared to ccRCC (11, 54, 91). The gene discussed is KDR; the disease is nonpapillary renal cell carcinoma.